Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Real World Outcomes of Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma Who Are Ineligible for Autologous Stem Cell Transplantation and Receive Commercially-Available Salvage Therapy

Emily C. Ayers, MD, David J Margolis, MD, Phyllis A. Gimotty, PhD, Daniel J. Landsburg, MD

Blood (2019) 134 (Supplement_1): 2893.

https://doi.org/10.1182/blood-2019-128815

Published: 2019

Journal Articles

Outcome of Patients with Aggressive B Cell Lymphomas Who Receive Second-Line Salvage Immunochemotherapy Following Treatment Failure of Intensive First-Line Immunochemotherapy

Emily C. Ayers, MD, Shaoying Li, MD, Jeffrey Medeiros, MD, David A. Bond, MD, Kami J. Maddocks, MD, Pallawi Torka, MD, Angel Mier Hicks, MD, Madeira Curry, Nina D. Wagner-Johnston, MD, Reem Karmali, MD, Amir Behdad, MD, Bita Fakhri, MDMPH, Brad S Kahl, MD, Michael C Churnetski, BS, Jonathon B. Cohen, MDMS, Nishitha Reddy, MD, Dipenkumar Modi, MD, Radhakrishnan Ramchandren, MD, Christina Howlett, PharmD, BCOP, Lori A. Leslie, MD, Samuel Cytryn, Catherine Diefenbach, MD, Rawan Faramand, MD, Julio C. Chavez, MD, Adam J Olszewski, MD, Yang Liu, MD, Stefan Klaus Barta, MDMRCP,MS, Dhruvika Mukhija, MD, Brian T. Hill, MD PhD, Helen Ma, MD, Jennifer E Amengual, MD, Sunita Nathan, MD, Sarit Assouline, Victor M. Orellana-Noia, MD, Craig A. Portell, MD, Ashwin Chandar, MD, Kevin A. David, MD, Anshu Giri, MD, Brian T. Hess, MD, Daniel J. Landsburg, MD

Blood (2018) 132 (Supplement 1): 453.

https://doi.org/10.1182/blood-2018-99-115527

Published: 2018

Journal Articles

Non-Effectiveness of Using RICE Post RDHAP or RDHAP Post RICE after Failure of First Line Salvage Therapy in DLBCL Patients Who Are Eligible for ASCT

Tony Ibrahim, MD MSc, Tarek Assi, Julien Lazarovici, MD, Maxime Annereau, PharmD, David Ghez, MD PhD, Jean-Marie Michot, MD, Julia Arfi-Rouche, Julien Rossignol, MD PhD, Veronique Vergé, Jacques Bosq, Peggy Dartigues-Cuillères, MD, Alina Danu, MD, Vincent Ribrag, MD

Blood (2018) 132 (Supplement 1): 4226.

https://doi.org/10.1182/blood-2018-99-117444

Published: 2018

Journal Articles

Efficacy of Salvage Chemotherapy in Diffuse Large B Cell Lymphoma with Primary Treatment Failure According to Putative Cell of Origin

Blood (2017) 130 (Supplement 1): 4141.

https://doi.org/10.1182/blood.V130.Suppl_1.4141.4141

Published: 2017

Journal Articles

A Phase 1/2 Study of Carfilzomib Combined with Rituximab, Ifosfamide, Carboplatin and Etoposide (C-RICE) in Patients with Transplant-Eligible, Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Pallawi Torka, MD, Seema Bhat, Kelvin P. Lee, MD, Alan Hutson, Jenna Nichols, Angela Kader, Cory Mavis, MSc, AnneMarie W Block, Sheila N. J. Sait, PhD, Bora E Baysal, MD PhD, Fadi Habib, MD, Vishala T. Neppalli, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2017) 130 (Supplement 1): 2822.

https://doi.org/10.1182/blood.V130.Suppl_1.2822.2822

Published: 2017

Journal Articles

Hematopoietic Stem Cell Transplantation for Diffuse Large B-Cell Lymphoma Harboring a 8q24/ MYC Rearrangement: A Retrospective Registry Study from the Japan Society for Hematopoietic Cell Transplantation

Tsutomu Takahashi, MD PhD, Ritsuro Suzuki, MD PhD, Koji Izutsu, MD PhD, Hideyuki Nakazawa, MD PhD, Sachiko Suzuki, MD PhD, Junya Kuroda, MD PhD, Katsuji Kaida, MD PhD, Hitoshi Ohno, MD PhD, Takahiro Fukuda, MD, Tatsuo Ichinohe, MD PhD, Yoshiko Atsuta, MD PhD, Junji Suzumiya, MD PhD

Blood (2016) 128 (22): 1868.

https://doi.org/10.1182/blood.V128.22.1868.1868

Published: 2016

Journal Articles

Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Relapsing after Autologous Stem Cell Transplantation (ASCT): An Analysis of Patients Included in the Coral Study

Eric Van Den Neste, MD PhD, Norbert Schmitz, MD, Nicolas Mounier, MD PhD, Devinder Gill, MB FRCPath FRACP FRCPA, Marek Trneny, MD, PhD, Prof., Noel Milpied, John A. Radford, MD, Nicolas Ketterer, Ofer Shpilberg, MD, Ulrich Dührsen, David Ma, MD, Josette Briere, Catherine Thieblemont, Gilles A. Salles, MD PhD, Craig Moskowitz, MD, Bertran Glass, Christian Gisselbrecht

Blood (2015) 126 (23): 517.

https://doi.org/10.1182/blood.V126.23.517.517

Published: 2015

Journal Articles

Poor Outcomes Among Patients Failing Dose-Adjusted EPOCH in Aggressive Lymphoma: A Collaborative, Retrospective Study

Jackie Vandermeer, BS, Allison M Winter, MD, Ajay K. Gopal, MD, Ryan D. Cassaday, MD, Brian T. Hill, MD PhD, Andrei R. Shustov, MD, Andrew J. Cowan, MD, David G. Maloney, MD PhD, Mazyar Shadman, MD MPH, Brian G. Till, MD, Lorinda Soma, MD, Oliver W. Press, MD PhD, Stephen D. Smith, MD

Blood (2015) 126 (23): 1518.

https://doi.org/10.1182/blood.V126.23.1518.1518

Published: 2015

Journal Articles

A Multi-Center, Non-Randomized Phase 2 Study of Ofatumumab in Combination with ICE-Chemotherapy (O-ICE) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Tiffany Tang, MBBS, MRCP, Cindy Lim, Miriam Tao, MBBS, MRCP, Richard Quek, MBBS, MRCP, Mohamad Farid, Won Seog Kim, MDPhD, Seok Jin Kim, MD PhD, Seong Hyun Jeong, Jong-Ho Won, MD, Nooraisyah Ismail, Soon Thye Lim, MBBS, MRCP

Blood (2014) 124 (21): 5465.

https://doi.org/10.1182/blood.V124.21.5465.5465

Published: 2014

Journal Articles

ICE (Ifosfamide, carboplatin, and etoposide) Was the Best Salvage Regimen in Patients with Relapsed or Refractory Malignant Lymphoma

Yoshiharu Kusano, MD, Yasuhito Terui, MD PhD, Noriko Nishimura, MD PhD, Kyoko Ueda, MD, Gunji Tadahiro, MD, Hideaki Nitta, MD, Yuko Mishima, MD#12288;PhD, Masahiro Yokoyama, MD, Naoko Tsuyama, MD, Kengo Takeuchi, MD PhD, Kiyohiko Hatake, MD PhD

Blood (2014) 124 (21): 5432.

https://doi.org/10.1182/blood.V124.21.5432.5432

Published: 2014

Journal Articles

Vorinostat, a Histone Deacetylase (HDAC) Inhibitor, Is Active in Chemotherapy Resistant B-Cell Non-Hodgkin Lymphoma and Enhances the Anti-Tumor Activity of Chemotherapy Agents

Kai Xue, MD, Juan Gu, PhD, Cory Mavis, MSc, Francisco Hernandez, MD, Myron S. Czuczman, MD, Ye Guo, MD

Blood (2014) 124 (21): 5486.

https://doi.org/10.1182/blood.V124.21.5486.5486

Published: 2014

Journal Articles

Diffuse Large B-Cell Lymphoma (DLBCL) Patients Failing Second-Line R-DHAP Or R-ICE Chemotherapy Included In The Coral Study

Eric Van Den Neste, MD, PhD, Christian Gisselbrecht, MD, Norbert Schmitz, Nicolas Mounier, MD, PhD, Devinder S Gill, David Linch FMedSci, Marek Trneny, MD, Ph.D.,, Noel Milpied, MD, PhD, John Radford, MD, Nicolas Ketterer, Ofer Shpilberg, MD, MPH, Ulrich Dührsen, MD, David Ma, MD, Josette Brière, MD, Catherine Thieblemont, MD, PhD, Gilles Andre Salles, MD, PhD, Craig H. Moskowitz, MD, Bertram Glass

Blood (2013) 122 (21): 764.

https://doi.org/10.1182/blood.V122.21.764.764

Published: 2013

Journal Articles

Bortezomib (BTZ) Inhibits p21-Dependent Senescence and Triggers Mitotic Catastrophe in Rituximab-Chemotherapy Resistant Cell Lines (RRCL)

Juan Gu, PhD, Francisco Hernandez-Ilizaliturri, MD, Gregory P. Kaufman, Cory Mavis, BSc, MSc, Myron S. Czuczman, MD

Blood (2012) 120 (21): 1655.

https://doi.org/10.1182/blood.V120.21.1655.1655

Published: 2012

Journal Articles

Feasibility and Outcome of High Dose Therapy Followed by Autologous Stem Cell Transplantation in Relapsed/Refractory Lymphoma in the Geriatric Population

Anthony R Mato, MD, Andre Goy, MD, Kathryn Waksmundzki, BS, Tatyana Feldman, MD, Tania Zielonka, RDC, Ewelina A Protomastro, BA, Coleen Bejot, MSN, NP-C, Gabriella Gadaleta, RN, APN-C, Scott D Rowley, MD, Michele L Donato, MD, Andrew L Pecora, MD, Katherine Facchin, RN, John P. Leonard, MD, Richard R. Furman, MD, Jia Ruan, MD, PhD, Tsiporah B Shore, Usama Gergis, MD, Morton Coleman, MD, Rebecca Elstrom, MD

Blood (2012) 120 (21): 4269.

https://doi.org/10.1182/blood.V120.21.4269.4269

Published: 2012

Journal Articles

Rituximab Maintenance Therapy in Diffuse Large B-Cell Lymphoma in a Multicenter Prospective Randomised Phase II Study,

Mathias Witzens-Harig, MD, Axel Benner, Michael Rieger, MD, Fabienne McClanahan, MD, Manfred Hensel, MD, Kai Neben, MD, Peter Dreger, MD, Eva Lengfelder, MD, Ingo Schmidt-Wolf, MD, Alwin Krämer, MD, PhD, Anthony D. Ho, MD

Blood (2011) 118 (21): 3700.

https://doi.org/10.1182/blood.V118.21.3700.3700

Published: 2011

Journal Articles

Prognostic Impact of Germinal Center (GC)/ Activated B-Cell (ABC) Classification Analysed by Immunochemistry, FISH Analysis and GEP, In Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): The Bio-CORAL Study

Catherine Thieblemont, MD, Josette Briere, MD, Nicolas Mounier, Hans-Ullrich Voelker, Wendy Cuccini, Edouard Hirchaud, Andreas Rosenwald, Andrew Jack, PhD, MB, Christer Sundstrom, MD, PhD, Sergio Cogliatti, Phlippe Trougouboff, Ludmila Boudova, Jean Soulier, Remi Houlgatte, Norbert Schmitz, MD, Philippe Gaulard, Christian Gisselbrecht, MD

Blood (2010) 116 (21): 993.

https://doi.org/10.1182/blood.V116.21.993.993

Published: 2010

Journal Articles

High-Dose Therapy and Autologous Stem Cell Transplant (HD-ASCT) for Transformed Non-Hodgkin Lymphoma (NHL) In the Rituximab Era

Makiko Ban-Hoefen, MD, Jonathan W. Friedberg, MD, Jennifer L. Kelly, PhD, MPH, Steven H. Bernstein, MD, Jane L. Liesveld, MD, Faith Young, MD, Richard I Fisher, MD, Louis Constine, MD, Michael Becker, MD, Gordon L. Phillips, II, MD

Blood (2010) 116 (21): 2393.

https://doi.org/10.1182/blood.V116.21.2393.2393

Published: 2010

Journal Articles

Independent Predictive Value of PET-CT Pre Transplant in Relapsed and Refractory Patients with CD20 Diffuse Large B-Cell Lymphoma (DLBCL) Included in the CORAL Study.

Marek Trneny, MD, Andre Bosly, MD, PhD, Krimo Bouabdallah, MD, David Ma, MD, Ofer Shpilberg, MD, MPH, Silvia Montoto, MD, Catherine Sebban, MD, Hans Hagberg, M.D., Craig H Moskowitz, MD, Norbert Schmitz, MD, PhD, Christian Gisselbrecht, MD

Blood (2009) 114 (22): 881.

https://doi.org/10.1182/blood.V114.22.881.881

Published: 2009

Journal Articles

The Effects of Rituximab Added to Front-Line or Salvage Chemotherapy in Diffuse Large B-Cell Lymphoma (DLBCL) Undergoing High-Dose Chemotherapy (HDC) and Autologous Stem Cell Transplant (ASCT).

Umeer Ashraf, MD, Ritika Mahajan, MBBS, Theresa Hahn, PhD, Shannon L Smiley, MD, Philip L. McCarthy, MD, Zale P. Bernstein, MD, Asher Alban Chanan-Khan, MD, Minoo Battiwala, Myron S. Czuczman, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2008) 112 (11): 1138.

https://doi.org/10.1182/blood.V112.11.1138.1138

Published: 2008

Journal Articles

R-ICE Versus R-DHAP in Relapsed Patients with CD20 Diffuse Large B-Cell Lymphoma (DLBCL) Followed by Stem Cell Transplantation and Maintenance Treatment with Rituximab or Not: First Interim Analysis on 200 Patients. CORAL Study.

Christian Gisselbrecht, MD, Norbert Schmitz, MD, Nicolas Mounier, MD, PhD, David Ma, MD, Marek Trneny, MD, Hans Hagberg, MD, David C. Linch, MD, Ofer Shpilberg, MD, Nicolas Ketterer, MD, Bertram Glass, MD, Andre Bosly, MD, Devinder Gill, MD, Philippe Gaulard, MD, Craig Moskowitz, MD

Blood (2007) 110 (11): 517.

https://doi.org/10.1182/blood.V110.11.517.517

Published: 2007

NARROW

Real World Outcomes of Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma Who Are Ineligible for Autologous Stem Cell Transplantation and Receive Commercially-Available Salvage Therapy

Outcome of Patients with Aggressive B Cell Lymphomas Who Receive Second-Line Salvage Immunochemotherapy Following Treatment Failure of Intensive First-Line Immunochemotherapy

Non-Effectiveness of Using RICE Post RDHAP or RDHAP Post RICE after Failure of First Line Salvage Therapy in DLBCL Patients Who Are Eligible for ASCT

Efficacy of Salvage Chemotherapy in Diffuse Large B Cell Lymphoma with Primary Treatment Failure According to Putative Cell of Origin

A Phase 1/2 Study of Carfilzomib Combined with Rituximab, Ifosfamide, Carboplatin and Etoposide (C-RICE) in Patients with Transplant-Eligible, Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Hematopoietic Stem Cell Transplantation for Diffuse Large B-Cell Lymphoma Harboring a 8q24/ MYC Rearrangement: A Retrospective Registry Study from the Japan Society for Hematopoietic Cell Transplantation

Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Relapsing after Autologous Stem Cell Transplantation (ASCT): An Analysis of Patients Included in the Coral Study

Poor Outcomes Among Patients Failing Dose-Adjusted EPOCH in Aggressive Lymphoma: A Collaborative, Retrospective Study

A Multi-Center, Non-Randomized Phase 2 Study of Ofatumumab in Combination with ICE-Chemotherapy (O-ICE) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

ICE (Ifosfamide, carboplatin, and etoposide) Was the Best Salvage Regimen in Patients with Relapsed or Refractory Malignant Lymphoma

Vorinostat, a Histone Deacetylase (HDAC) Inhibitor, Is Active in Chemotherapy Resistant B-Cell Non-Hodgkin Lymphoma and Enhances the Anti-Tumor Activity of Chemotherapy Agents

Diffuse Large B-Cell Lymphoma (DLBCL) Patients Failing Second-Line R-DHAP Or R-ICE Chemotherapy Included In The Coral Study

Bortezomib (BTZ) Inhibits p21-Dependent Senescence and Triggers Mitotic Catastrophe in Rituximab-Chemotherapy Resistant Cell Lines (RRCL)

Feasibility and Outcome of High Dose Therapy Followed by Autologous Stem Cell Transplantation in Relapsed/Refractory Lymphoma in the Geriatric Population

Rituximab Maintenance Therapy in Diffuse Large B-Cell Lymphoma in a Multicenter Prospective Randomised Phase II Study,

Prognostic Impact of Germinal Center (GC)/ Activated B-Cell (ABC) Classification Analysed by Immunochemistry, FISH Analysis and GEP, In Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): The Bio-CORAL Study

High-Dose Therapy and Autologous Stem Cell Transplant (HD-ASCT) for Transformed Non-Hodgkin Lymphoma (NHL) In the Rituximab Era

Independent Predictive Value of PET-CT Pre Transplant in Relapsed and Refractory Patients with CD20 Diffuse Large B-Cell Lymphoma (DLBCL) Included in the CORAL Study.

The Effects of Rituximab Added to Front-Line or Salvage Chemotherapy in Diffuse Large B-Cell Lymphoma (DLBCL) Undergoing High-Dose Chemotherapy (HDC) and Autologous Stem Cell Transplant (ASCT).

R-ICE Versus R-DHAP in Relapsed Patients with CD20 Diffuse Large B-Cell Lymphoma (DLBCL) Followed by Stem Cell Transplantation and Maintenance Treatment with Rituximab or Not: First Interim Analysis on 200 Patients. CORAL Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only